Index changes put Stryker’s robotics story in focus

Stryker (SYK) has been dropped from several Russell growth benchmarks, just as analysts highlight rising adoption of its Mako robotic system in ambulatory surgery centers and growing interest in the company’s flexible robotics contract structures.

Despite being removed from several Russell growth indices, Stryker’s recent 7 day share price return of 4.73% and 30 day share price return of 7.88% point to rebuilding momentum, even as the 1 year total shareholder return is down 14.48%.

If Stryker’s robotics story has your attention, it can be useful to see what else is moving in medical technology and automation through the 29 robotics and automation stocks

For Stryker, a 7 day rebound and a 1 year return still down 14.48% sit awkwardly beside upbeat commentary on Mako and robotics contracts. Is the recent move a sentiment reset, or a business story investors are re-pricing?

Most Popular Narrative: 14.8% Undervalued

Compared to Stryker’s last close at $329.74, the most followed narrative pegs fair value at $386.80, framing the recent rebound against a higher implied bar.

Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues, which is expected to accelerate both revenue and margin expansion over time.

Curious what kind of revenue climb and margin lift are built into that story? The narrative leans on steady procedure growth and a richer earnings mix. The full set of assumptions is where the real tension shows up.

Result: Fair Value of $386.80 (UNDERVALUED)

However, Stryker’s story can change quickly if supply chain strains deepen, or if tariff and reimbursement pressures bite harder, squeezing margins and challenging today’s fair value narrative.

Another View on Stryker’s Valuation

The fair value narrative for Stryker at $386.80 leans on future earnings power, yet the current P/E of 37.9x tells a different story. It sits well above the US Medical Equipment industry at 26.6x, peers at 29.7x, and even the 34.3x fair ratio our model suggests the market could move toward. This raises the question of how much optimism is already in the price.

For a closer look at what this gap could mean for upside risk or downside risk, start with the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed tone around Stryker has you torn, this is the moment to look at the full picture yourself and move quickly. Weigh the upside case against the concerns by checking the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Stryker?

If Stryker has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to uncover more focused ideas that match your style.

• Target resilient cash generators by scanning companies with strong finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Hunt for potential mispricings by filtering for companies that look attractively priced using the 45 high quality undervalued stocks.
• Prioritise stability and staying power by reviewing 74 resilient stocks with low risk scores before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.